Physician profile
Sven Wang
NPI 1134707805
$2,965.27
in general payments reported to CMS, 2019-2025
9 companies · $2,311 in 2025
The $2,311 reported for 2025 was more than what 97% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $654 · 2025: $2,311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $1,572 · Food and Beverage: $1,394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $1,571.52 |
| Food and Beverage | $1,393.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jubilant Hollisterstier LLC | $1,571.52 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $404.39 | 2024-2025 | Tezspire, Fasenra, Airsupra |
| Blueprint Medicines Corporation | $333.23 | 2024-2025 | Ayvakit |
| Ars Pharmaceuticals Operations, INC. | $240.27 | 2025 | Neffy |
| Novartis Pharmaceuticals Corporation | $170.55 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $120.81 | 2025 | Dupixent |
| Incyte Corporation | $58.25 | 2025 | Opzelura |
| Genzyme Corporation | $47.20 | 2024 | |
| Ionis Pharmaceuticals, INC. | $19.05 | 2025 | Tryngolza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sven Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.